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Prosthetic joint infection (PJI) is the most common cause of failure of total joint arthroplasty, but a gold standard for PJI diagnosis
is still lacking. Advanced glycation end products (AGEs) are proinﬂammatory molecules inducing intracellular oxidative stress
(OS) after binding to their cell membrane receptors (RAGE). The aim of this study was to evaluate plasmatic soluble receptor
for advanced glycation end products (sRAGE), as a new OS and infection marker correlating sRAGE to the level of OS and
antioxidant defenses, in PJI, in order to explore the possible application of this new biomarker in the early diagnosis of PJI.
Plasmatic sRAGE levels (by ELISA assay), plasma antioxidant total defenses (by lag time method), plasma reactive oxygen
species (ROS), and thiobarbituric acid reactive substance (TBARS) levels (by colorimetric assay) were evaluated in 11 PJI
patients and in 30 matched controls. ROS and TBARS were signiﬁcantly higher (p < 0 001) while plasma total antioxidant
capacity and sRAGE were signiﬁcantly lower (p < 0 01) in patients with PJI compared to controls. Our results conﬁrm the OS in
PJI and show a strong negative correlation between the level of sRAGE and oxidative status, suggesting the plasmatic sRAGE as
a potential marker for improving PJI early diagnosis.
1. Introduction
The numbers of primary total hip and total knee arthroplas-
ties have been increasing over the past decade. Prosthetic
joints improve the quality of life, but they may fail, thus
requiring revision surgery. Infection is the most serious com-
plication, occurring in 0.8 to 1.9% of knee arthroplasties and
0.3 to 1.7% of hip arthroplasties. Nowadays, a wide number
of tests are available for prosthetic-joint-associated infection
(PIJ) diagnosis, ranging from haematological markers of
infection and inﬂammation, intraoperative culture, and
histology analysis. Nevertheless, there is still a lack of gold
standards for the diagnosis of PIJ [1, 2] because the clinical
presentation of PJI is often ambiguous and classical inﬂam-
matory markers can bemisleading [3, 4]. In order to optimize
the diagnostic process, infection biomarkers with fast
response and high sensitivity and speciﬁcity for infection
are needed [5–8].
Among the scenario of infection diagnosis, an emerging
role has been recently described for oxidative stress (OS)
evaluation [9, 10]. Inﬂammatory response induces an over-
production of ROS, exacerbating organ and tissue injuries
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[11]. PJI is mostly due to Staphilococcus aureus infection,
which induces massive leukocyte recruitment, mainly neu-
trophils, to the site of infection. Neutrophils represent the
ﬁrst line defense against pathogen invasion, and, in order to
combat S. aureus, neutrophils are able both to engulf bacteria
through phagocytosis and to directly kill the bacteria by ROS
production, leading to oxidative burst [12]. Oxidative burst
is a major event characterizing the inﬂammatory response,
and for this reason, markers of oxidative stress are currently
used in the clinical evaluation of sepsis [11, 13], but at the
moment no evidence has described so far the use of OS
stress evaluation in PJI diagnosis.
Recent evidences correlated OS to the levels of advanced
glycation end products (AGEs): In particular, oxidative stress
has been recently described as able to increase the formation
of AGEs [14, 15]. AGEs are a heterogeneous group of irre-
versible adduct formed by the nonenzymatic glycation and
glycoxidation of proteins, nucleic acids, and lipids. AGEs
interact with their receptors RAGE, which exist as a
membrane-bound form and a soluble plasmatic form, soluble
receptor for advanced glycation end products (sRAGE).
Interaction of AGEs with the cell membrane-bound receptor
RAGE activates NF-κB, increases gene expression and
production of inﬂammatory cytokines, and increases the pro-
duction of ROS [16]. On the contrary, sRAGE act as a decoy
receptor counteracting the action of RAGE by competing for
AGE ligand, thus having a protective role against deleterious
eﬀects mediated by AGE-RAGE axis [15]. Soluble RAGE
have been recently proposed as a circulating biomarker indi-
cating the status of disease [17] and oxidative stress [18, 19].
The aim of the present study was to evaluate the diagnos-
tic value of plasmatic sRAGE, as new oxidative stress and
infection marker, correlating it to the level of OS and antiox-
idant defenses, in postoperative prosthetic joint infection
(PJI), in order to explore the possible application of this
new biomarker in the early diagnosis of PJI.
2. Materials and Methods
2.1. Subjects. Eleven patients with prosthetic-joint-associated
infection (PJI), aged 60.2± 16, were recruited from C.R.I.O.
Unit, IRCCS Galeazzi, Milan, Italy. Controls were 30 adult
volunteer blood donors, aged 56.1± 19.41, from the Italian
association of blood volunteers (AVIS) in Milan, Italy. This
investigation conforms to the principles outlined in the
Declaration of Helsinki. Signed informed written consent
was obtained from all subjects before their participation in
the study. The manuscript is part of a larger project on the
search of new biomarkers for PJI diagnosis (“Ricerca Corrente
note L4061”), approved by the local ethical committee.
2.2. Materials. Commercial chemicals were of the highest
available grade. The water routinely used was freshly redis-
tilled in a glass apparatus. Bovine serum albumin (BSA),
copper(II) sulphate (CuSO4), 2-thiobarbituric acid (TBA),
butylated hydroxyl toluene (BHT), and 1,1,3,3-tetramethox-
ypropane (TMP) were purchased from Sigma Chemical Co.
(St. Louis, MO, USA). All other reagents were purchased
from Merck (Darmstad, Germany). d-ROMs kit test was
purchased from Diacron International (Grosseto, Italy).
2.3. Blood Samples and Serum/Plasma Preparation. Plasma
was prepared from heparinized venous blood. After collec-
tion, blood samples were immediately centrifuged for
15min at 3000×g and plasma immediately withdrawn and
stored at −70°C until ELISA assay and evaluation of plasmatic
oxidative status.
2.4. Evaluation of Plasma Oxidative. Plasma lipid hydroper-
oxide levels (ROS) were determined colorimetrically accord-
ing to Trotti et al. [20] and expressed as H2O2 equivalents.
Thiobarbituric acid reactive substances (TBARS) in
plasma samples were measured spectrophotometrically.
Brieﬂy, the sample was mixed with 10mmol/L BHT (in abso-
lute ethanol), 1% orthophosphoric acid (in HCl 0.1N), and
0.6% TBA and then heated at 90°C for 45min. After cooling,
the pink MDA-(TBA)2 adduct was extracted in n-butanol
and the absorbance of the organic phase was determined at
535 nm. The absorbance of blank (plasma without TBA reac-
tive) was subtracted from that of the corresponding sample.
TMP was used as standard of MDA, whose concentrations
in samples were calculated with respect to a standard curve
(range 1–10μmol/L).
The kinetics of plasma oxidation, induced by addition of
CuSO4 0.5M, were determined at 37
°C by monitoring the
development of ﬂuorescence at 430nm, setting the excitation
at 355 nm as described by Cervato et al. [21] by Multilabel
Counter Wallac 1420 from PerkinElmer. This method allows
the evaluation of the peroxidation kinetics monitored follow-
ing the formation of ﬂuorescent adducts originating from the
reaction of aldehydes (derived from lipid peroxidation pro-
moted by Cu++ bound to apolipoproteins) with amino
groups of plasma proteins and/or phospholipids. The kinetic
is expressed by a sigmoid curve that can be divided into an
initial latency phase, followed by a second propagation phase.
The initial latency phase (lag time, expressed in minutes and
calculated as the intercept of the linear regression of the
propagation phase with that of the latency phase) is an index
of lipoprotein resistance to peroxidation.
2.5. sRAGE ELISA Assay. Levels of soluble RAGE in plasma
were determined by ELISA commercial assays, according to
the manufacturers’ instructions (sRAGE: R&D Systems,
Minneapolis, Minnesota, USA).
For the sRAGE assay, the sensitivity was 4.44 pg/mL, and
intra- and interassay coeﬃcients of variation were 2.4% and
4.7%, respectively.
2.6. Statistical Analysis. The Shapiro–Wilk test showed no
signiﬁcative diﬀerence from normal distribution. Therefore,
parametric techniques were used. Means were compared by
Student t-test. The Pearson correlation coeﬃcient (r2) was
calculated to determine the correlation between values
measured by diﬀerent assays. Distribution and correlation
analysis were performed using the SPSS STATISTIC 24
package (SPSS Inc., Chicago, IL, USA).
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Statistical analysis of receiver operating characteristic
(ROC) curves and area under the curve (AUC) was per-
formed using Prism 5 software.
3. Results
3.1. Plasma Peroxidation Parameters. Plasma peroxidation
parameters are reported in Figure 1. As expected, hydro-
peroxide levels (Figure 1(a)) of PJI patients (mean± SD
40.4± 2.4mg/dL; range 37.4–45.7mg/dL) are signiﬁcantly
(p < 0 001) higher (+72%) than the controls (mean± SD
23.51± 2.52mg/dL; range 19.17–29.65mg/dL); the time
interval necessary for inhibiting the Cu-induced peroxidative
process (lag time, Figure 1(b)) is signiﬁcantly (p < 0 01)
lower (−20%) in PJI patients (107± 18min; 70–130min)
than in the control group (133± 17min; 110–180min), and
TBARS levels (Figure 1(c)) are signiﬁcantly (p < 0 001)
higher (+132%) in PJI patients (8.03± 1.31μmol/L; 5.60–
10.20μmol/L) with respect to the control group (3.46±
0.61μmol/L; 2.42–4.61μmol/L).
3.2. sRAGE. As shown in Figure 2, sRAGE levels are signiﬁ-
cantly (p < 0 001) lower (−58%) in PJI subjects (442.96±
221.21 pg/mL; 202, 81–950, 39 pg/mL) than in the control
group (1044.84± 359.13 pg/mL; 609.53–1794.03 pg/mL).
3.3. Correlation Analysis. As shown in Figure 3, in PJI
patients, sRAGE show a linear signiﬁcant (p < 0 05) positive
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Figure 1: Plasma peroxidation parameters. Hydroperoxides are expressed as equivalent of H2O2 mg/dL of plasma. Values are expressed as
mean ± standard deviation (SD). ∗∗p < 0 01 controls versus PJI subjects. ∗∗∗p < 0 001 controls versus PJI subjects.
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correlation (r2 = 0.614) with lag time and a linear signiﬁcant
(p < 0 05) negative correlation (r2 =−0.609) with TBARS
levels, as well as a linear negative (even not signiﬁcant) cor-
relation with ROS levels, suggesting this parameter as a
good/useful marker of oxidative status/stress.
3.4. ROC Curve Analysis. In order to evaluate the diagnostic
potential of the biomarker analyzed in the detection of PJI,
ROC curve analysis was performed for all four parameters
and AUC was calculated.
As shown in Figure 4, each parameter displayed an AUC
higher than the cut-oﬀ 0.8 considered the threshold of
AUC to consider a parameter clinically acceptable. The
AUC resulted 0.951, 0.969, 0.883, and 0.993 for sRAGE,
ROS, lag time, and TBARS, respectively.
4. Discussion
The numbers of primary total hip and total knee arthro-
plasties increased over the past decade, but the complications
due to defective implants and prosthetic infection are
still challenging.
Several studies have underlined the crucial role of
oxidative stress in the pathophysiologic “vicious cycle” of
inﬂammation, deeply related to infection [22].
ROS are normally generated by cellular metabolism and
at low or moderate concentrations play physiological roles
including cellular response to infectious agents. Oxidative
stress occurs when the production of ROS and other reactive
species overwhelm the capacity of cellular antioxidant
defenses to detoxify these potentially injurious species. Redox
imbalance can be produced through an increased generation
of ROS and by the decrease of cellular antioxidant molecules.
Oxidative stress has been implicated in pathological condi-
tions associated with diﬀerent human inﬂammatory diseases.
Excessive ROS have been linked to pathogenesis of cancer,
cardiovascular disease, atherosclerosis, hypertension, ische-
mia/reperfusion injury, diabetes mellitus, neurodegenerative
diseases, rheumatoid arthritis, pulmonary disease, and ageing
[23–27]. Increasing data suggest that oxidative stress is also
involved in the pathogenesis of infectious diseases [28].
Among the factors regulating oxidative stress, an important
role is played by the axis AGE-RAGE. On the one hand,
AGE-RAGE axis activated NADPH oxidase; on the other
hand, it induces the formation of reactive oxygen species
(ROS), which induce cellular damage acting as cellular toxi-
cant. This eﬀect is deﬁned as AGE-RAGE-oxidative stress
(AROS) [29], and it is involved in the pathogenesis of diﬀer-
ent inﬂammatory diseases. The function of AGE-RAGE axis
is counterbalanced by the soluble receptor sRAGE, which act
as a decoy for AGE ligands, exerting a protective role against
tissue damages induced by AROS. Being a circulating mole-
cule, sRAGE have been investigated as potential biomarker
of oxidative stress [30, 31] and disease status [17], but
evidences about the diagnostic role of sRAGE as marker of
oxidative stress and PJI are still lacking.
On these bases, the study was aimed to evaluate the
diagnostic value of plasmatic sRAGE by correlating it to the
plasmatic levels of OS and antioxidant defenses in postoper-
ative prosthetic joint infection patients (PJI), in order to
explore the possible application of this new biomarker in
the early diagnosis of PJI.
The oxidative stress (OS) has been evaluated using classi-
cal methodologies (plasma hydroperoxide levels and thiobar-
bituric acid reactive substances, TBARS) and measuring total
plasma antioxidant capacity by lag time method, a simple
and reproducible assay used to evaluate the “oxidation resis-
tance” of plasma lipoproteins. This analytical approach has
been successfully applied for monitoring plasmatic peroxida-
tion risk in patients with oxidative-related pathologies (such
as, diabetes, cancer, hypertension, Down syndrome, chronic
renal failure, etc.) [32–34] as well as to evaluate the eﬀects
of antioxidant treatments.
The evaluation of both markers of peroxidation and
plasma oxidative defenses (Figure 1) highlights a condition
of strong oxidative stress in PJI as occurring in other
pathologies [33].
Consistently with these results, sRAGE resulted signiﬁ-
cantly lower in PJI patients, conﬁrming its protective role as
decoy receptor for AGE ligand.
This role seems to be also conﬁrmed by the correlation
analysis, which indicated a negative correlation of sRAGE
with ROS, and TBARS levels, and a positive correlation of
sRAGE with lag time. The oxidative stress increase observed
in PJI, as indicated by the analyzed OS parameters, corre-
sponds to a decrease of lipoprotein resistance to peroxida-
tion, measured by lag time, and it consistently correlates
with the decrease of sRAGE levels.
The diagnostic role of circulating low levels of sRAGE
is controversial. Serum levels of sRAGE are lower in
healthy subjects than in patients with coronary artery
disease and atherosclerotic burden disease in nondiabetic
subjects [35–37]. Low levels of sRAGE have also been
described in hypercholesterolemia [38], essential hyperten-
sion [39], Alzheimer disease, and vascular dementia.
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On the other hand, other evidences described elevated
circulating sRAGE in type 2 diabetic patients with coronary
artery disease or with atherosclerotic burden. The reason
for this elevated levels of sRAGE could be due to elevated
levels of matrix metalloproteinases (MMPs) in diabetes
and renal disease, which would increase the formation of
sRAGE [17].
PJI induces an inﬂammatory response involving cytokine
production and oxidative stress; therefore, the reduction
of the decoy receptor sRAGE in PJI patients compared
to the control group is consistent with a loss of sRAGE
protective role.
The diagnostic value of sRAGE and oxidative stress
biomarkers was further evaluated by the analysis of receiver
operating characteristics (ROC) curve and AUC (area under
the curve).
The closer the curve was to the upper left-hand corner of
the SROC curve plot, the better the overall accuracy of the
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test. An area under the ROC curve between 0.90 and 1.0 is
considered as excellent diagnostic accuracy, between 0.80
and 0.90 as good, between 0.70 and 0.80 as fair, between
0.60 and 0.70 as poor, and between 0.50 and 0.60 as fail [40].
SRAGE displayed a good AUC (0.951), indicating that
this molecule has a good diagnostic value and it could be con-
sidered as a new biomarker for the diagnosis of PJI. Similarly,
the parameters evaluating the oxidative status, ROS, lag time,
and TBARS displayed good AUC values (0.969, 0.833, and
0.933, resp.), far over the value of 0.8 which is considered in
the clinical practice the lower cut-oﬀ for a parameter to be
considered clinically acceptable. These results on the one
hand indicate the good diagnostic tool of the oxidative
biomarkers in the detection of PJI and on the other hand
indicate that sRAGE can be considered a good marker of
oxidative status and, therefore, also a good biomarker of PJI.
5. Conclusion
Our results conﬁrm the substantial OS in PJI and show a
strong negative correlation between the level of sRAGE
and oxidative stress, suggesting that plasmatic sRAGE can
be considered as potential OS markers. This new approach
could represent a useful diagnostic tool for improving
prosthesis joint infection diagnosis, where a clear detection
of the infection is still lacking, in addition to routine
inﬂammatory parameters.
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